Cas:1150114-52-5 (2-Fluoro-5-hydroxyphenyl)boronic acid manufacturer & supplier

Chemical Name:(2-Fluoro-5-hydroxyphenyl)boronic acid

CAS.NO:1150114-52-5

Synonyms:(2-fluoro-5-hydroxyphenyl)boronic acid

Molecular Formula:C₆H₆BFO₃

Molecular Weight:155.91900

HS Code:2931900090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:60.69000

Exact Mass:156.03900

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like (2-fluoro-5-hydroxyphenyl)boronic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(2-fluoro-5-hydroxyphenyl)boronic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(2-fluoro-5-hydroxyphenyl)boronic acid Use and application,(2-fluoro-5-hydroxyphenyl)boronic acid technical grade,usp/ep/jp grade.

Related News: Biogen has said that some 1.5 million Americans with early-stage Alzheimer’s will be eligible for the drug, priced at an average of $56,000 per year, with the federal Medicare insurance program for seniors likely on the hook for most of the cost. (2-Fluoro-5-hydroxyphenyl)boronic acid manufacturer In an August overhaul to its drug administration law, Beijing said conditional approval could be granted to some still-under-research medicines of ��predictable�� clinical value for life-threatening diseases for which effective treatment is not immediately available. (2-Fluoro-5-hydroxyphenyl)boronic acid supplier ��Once these risks have been identified then a project team can be put together combining the necessary expertise to provide the integrated services and tailored support to ensure continuity of supply from beginning to end.�� (2-Fluoro-5-hydroxyphenyl)boronic acid vendor Two sources familiar with the situation told Reuters that the agency had cleared about 10 million doses. (2-Fluoro-5-hydroxyphenyl)boronic acid factory In an August overhaul to its drug administration law, Beijing said conditional approval could be granted to some still-under-research medicines of ��predictable�� clinical value for life-threatening diseases for which effective treatment is not immediately available.